Drug major Lupin has appointed Kurt Nielsen president of US-based Gavis-Novel Somerset business.
Nielsen will be responsible for overall operations of the Gavis-Novel Somerset business and will be based out of Somerset, New Jersey, Lupin said in a regulatory filing.
"Kurt joins us at an exciting phase of Lupin's evolution as a global generics powerhouse and an emerging specialty pharmaceutical company, having closed the Gavis acquisition recently," Lupin Ltd CEO Vinita Gupta said.
The company has ambitious plans to further strengthen and expand its generic as well as specialty business in the US, she added.
Nielsen joins Lupin from Sandoz where he held dual responsibility of being the global head of product development as well as being the vice-president of US product development, portfolio and launch management for generic and brand products.
With the successful completion of the USD 880 million Gavis acquisition earlier this month, Lupin now has the fifth largest abbreviated new drug application (ANDA) pipeline pending approval with the USFDA.
